GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (STU:05Y) » Definitions » Gross Margin %

Vivoryon Therapeutics NV (STU:05Y) Gross Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Vivoryon Therapeutics NV Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Vivoryon Therapeutics NV's Gross Profit for the six months ended in Dec. 2023 was €-3.62 Mil. Vivoryon Therapeutics NV's Revenue for the six months ended in Dec. 2023 was €-3.62 Mil. Therefore, Vivoryon Therapeutics NV's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Vivoryon Therapeutics NV's Gross Margin % or its related term are showing as below:

STU:05Y' s Gross Margin % Range Over the Past 10 Years
Min: 85.43   Med: 85.47   Max: 85.5
Current: 85.5


During the past 13 years, the highest Gross Margin % of Vivoryon Therapeutics NV was 85.50%. The lowest was 85.43%. And the median was 85.47%.

STU:05Y's Gross Margin % is ranked better than
80.27% of 750 companies
in the Biotechnology industry
Industry Median: 60.53 vs STU:05Y: 85.50

Vivoryon Therapeutics NV had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Vivoryon Therapeutics NV was 0.00% per year.


Vivoryon Therapeutics NV Gross Margin % Historical Data

The historical data trend for Vivoryon Therapeutics NV's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV Gross Margin % Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 85.43 - 85.50

Vivoryon Therapeutics NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivoryon Therapeutics NV's Gross Margin %

For the Biotechnology subindustry, Vivoryon Therapeutics NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivoryon Therapeutics NV's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's Gross Margin % falls into.



Vivoryon Therapeutics NV Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Vivoryon Therapeutics NV's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-3.1 / -3.62
=(Revenue - Cost of Goods Sold) / Revenue
=(-3.62 - -0.525) / -3.62
=85.50 %

Vivoryon Therapeutics NV's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-3.6 / -3.62
=(Revenue - Cost of Goods Sold) / Revenue
=(-3.62 - 0) / -3.62
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Vivoryon Therapeutics NV  (STU:05Y) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Vivoryon Therapeutics NV had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Vivoryon Therapeutics NV Gross Margin % Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivoryon Therapeutics NV (STU:05Y) Business Description

Traded in Other Exchanges
Address
Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (STU:05Y) Headlines

No Headlines